70
Views
75
CrossRef citations to date
0
Altmetric
Article

Leucine-Rich Repeat Kinase 2 Binds to Neuronal Vesicles through Protein Interactions Mediated by Its C-Terminal WD40 Domain

, , , , , , , , , , , , , , , , , , , & show all
Pages 2147-2161 | Received 23 Jul 2013, Accepted 18 Mar 2014, Published online: 20 Mar 2023

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Daleum Nam, Hyejung Kim, Dong-Joo Choi, Yun-Hee Bae, Byoung Dae Lee, Ilhong Son & Wongi Seol. (2018) Characterization of Parkinson’s disease-related pathogenic TMEM230 mutants. Animal Cells and Systems 22:2, pages 140-147.
Read now
Paul Galatsis. (2017) Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016). Expert Opinion on Therapeutic Patents 27:6, pages 667-676.
Read now

Articles from other publishers (73)

Xiaojuan Zhang & Arjan Kortholt. (2023) LRRK2 Structure-Based Activation Mechanism and Pathogenesis. Biomolecules 13:4, pages 612.
Crossref
Xu Tang, Shuaishuai Xing, Mingkang Ma, Ziwei Xu, Qianwen Guan, Yuting Chen, Feng Feng, Wenyuan Liu, Tingkai Chen, Yao Chen & Haopeng Sun. (2023) The Development and Design Strategy of Leucine-Rich Repeat Kinase 2 Inhibitors: Promising Therapeutic Agents for Parkinson’s Disease. Journal of Medicinal Chemistry 66:4, pages 2282-2307.
Crossref
Tatou Iseki, Yuzuru Imai & Nobutaka Hattori. (2023) Is Glial Dysfunction the Key Pathogenesis of LRRK2-Linked Parkinson’s Disease?. Biomolecules 13:1, pages 178.
Crossref
Ignacio Mata, Philippe Salles, Mario Cornejo-Olivas, Paula Saffie, Owen A. Ross, Xylena Reed & Sara Bandres-Ciga. 2023. Precision Medicine in Neurodegenerative Disorders, Part II. Precision Medicine in Neurodegenerative Disorders, Part II 133 154 .
Toshiki Tezuka, Daisuke Taniguchi, Mariko Sano, Tomoyo Shimada, Yutaka Oji, Taiji Tsunemi, Aya Ikeda, Yuanzhe Li, Hiroyo Yoshino, Jun Ogata, Kahori Shiba-Fukushima, Manabu Funayama, Kenya Nishioka, Yuzuru Imai & Nobutaka Hattori. (2022) Pathophysiological evaluation of the LRRK2 G2385R risk variant for Parkinson’s disease. npj Parkinson's Disease 8:1.
Crossref
María Dolores Pérez-Carrión, Inmaculada Posadas, Javier Solera & Valentín Ceña. (2022) LRRK2 and Proteostasis in Parkinson’s Disease. International Journal of Molecular Sciences 23:12, pages 6808.
Crossref
Lara Ottaviani, Rio P. Juni, Ricardo C. de Abreu, Marida Sansonetti, Vasco Sampaio-Pinto, Julie Halkein, Jana C. Hegenbarth, Nadja Ring, Kevin Knoops, Jordy M.M. Kocken, Carlos de Jesus, Auriane C. Ernault, Hamid el Azzouzi, Frank Rühle, Servé Olieslagers, Hugo Fernandes, Lino Ferreira, Luca Braga, Monika Stoll, Diana S. Nascimento, Leon J. de Windt & Paula A. da Costa Martins. (2022) Intercellular transfer of miR-200c-3p impairs the angiogenic capacity of cardiac endothelial cells. Molecular Therapy 30:6, pages 2257-2273.
Crossref
Federica Albanese, Chiara Domenicale, Mattia Volta & Michele Morari. (2022) Modeling Parkinson's disease in LRRK2 mice: focus on synaptic dysfunction and the autophagy-lysosomal pathway. Biochemical Society Transactions 50:1, pages 621-632.
Crossref
Manish Verma, Britney N. Lizama & Charleen T. Chu. (2022) Excitotoxicity, calcium and mitochondria: a triad in synaptic neurodegeneration. Translational Neurodegeneration 11:1.
Crossref
Lucia Iannotta & Elisa Greggio. (2021) LRRK2 signaling in neurodegeneration: two decades of progress. Essays in Biochemistry 65:7, pages 859-872.
Crossref
Andrea Maset, Marco Albanesi, Antonio di Soccio, Martina Canova, Marco dal Maschio & Claudia Lodovichi. (2021) Aberrant Patterns of Sensory-Evoked Activity in the Olfactory Bulb of LRRK2 Knockout Mice. Cells 10:11, pages 3212.
Crossref
Jinru Zhang, Kai Li, Xiaobo Wang, Amber M. Smith, Bo Ning, Zhaohui Liu, Chunfeng Liu, Christopher A. Ross & Wanli W. Smith. (2021) Curcumin Reduced H2O2- and G2385R-LRRK2-Induced Neurodegeneration. Frontiers in Aging Neuroscience 13.
Crossref
Dominika Natalia Wojewska & Arjan Kortholt. (2021) LRRK2 Targeting Strategies as Potential Treatment of Parkinson’s Disease. Biomolecules 11:8, pages 1101.
Crossref
Francesca Pischedda, Maria Daniela Cirnaru, Luisa Ponzoni, Michele Sandre, Alice Biosa, Maria Perez Carrion, Oriano Marin, Michele Morari, Lifeng Pan, Elisa Greggio, Rina Bandopadhyay, Mariaelvina Sala & Giovanni Piccoli. (2021) LRRK2 G2019S kinase activity triggers neurotoxic NSF aggregation. Brain 144:5, pages 1509-1525.
Crossref
Laura Doblado, Claudia Lueck, Claudia Rey, Alejandro K. Samhan-Arias, Ignacio Prieto, Alessandra Stacchiotti & Maria Monsalve. (2021) Mitophagy in Human Diseases. International Journal of Molecular Sciences 22:8, pages 3903.
Crossref
Jun Ogata, Kentaro Hirao, Kenya Nishioka, Arisa Hayashida, Yuanzhe Li, Hiroyo Yoshino, Soichiro Shimizu, Nobutaka Hattori & Yuzuru Imai. (2021) A Novel LRRK2 Variant p.G2294R in the WD40 Domain Identified in Familial Parkinson’s Disease Affects LRRK2 Protein Levels. International Journal of Molecular Sciences 22:7, pages 3708.
Crossref
Francesca Pischedda & Giovanni Piccoli. (2021) LRRK2 at the pre‐synaptic site: A 16‐years perspective. Journal of Neurochemistry 157:2, pages 297-311.
Crossref
Jolanta Dorszewska, Marta Kowalska, Michał Prendecki, Thomas Piekut, Joanna Kozłowska & Wojciech Kozubski. (2021) Oxidative stress factors in Parkinson’s disease. Neural Regeneration Research 16:7, pages 1383.
Crossref
Yixuan Zhang, Jiali Wang, Xiaoquan Liu & Haochen Liu. (2020) Exploring the role of RALYL in Alzheimer’s disease reserve by network-based approaches. Alzheimer's Research & Therapy 12:1.
Crossref
L. Iovino, M.E. Tremblay & L. Civiero. (2020) Glutamate-induced excitotoxicity in Parkinson's disease: The role of glial cells. Journal of Pharmacological Sciences 144:3, pages 151-164.
Crossref
Ahmed Soliman, Fatma Nihan Cankara & Arjan Kortholt. (2020) Allosteric inhibition of LRRK2, where are we now. Biochemical Society Transactions 48:5, pages 2185-2194.
Crossref
Xinyi Li, Mingyu Ye, Yue Wang, Ming Qiu, Tingting Fu, Jian Zhang, Bin Zhou & Shaoyong Lu. (2020) How Parkinson's disease-related mutations disrupt the dimerization of WD40 domain in LRRK2: a comparative molecular dynamics simulation study. Physical Chemistry Chemical Physics 22:36, pages 20421-20433.
Crossref
Caroline L. Benn & Lee A. Dawson. (2020) Clinically Precedented Protein Kinases: Rationale for Their Use in Neurodegenerative Disease. Frontiers in Aging Neuroscience 12.
Crossref
Naila Kuhlmann & Austen J. Milnerwood. (2020) A Critical LRRK at the Synapse? The Neurobiological Function and Pathophysiological Dysfunction of LRRK2. Frontiers in Molecular Neuroscience 13.
Crossref
Shalini Padmanabhan, Brian K. Fiske & Marco A.S. Baptista. (2020) The Michael J. Fox Foundation’s Strategies for Accelerating Translation of LRRK2 into Therapies for Parkinson Disease. Cells 9:8, pages 1878.
Crossref
Andrea Mancini, Petra Mazzocchetti, Miriam Sciaccaluga, Alfredo Megaro, Laura Bellingacci, Dayne A. Beccano-Kelly, Massimiliano Di Filippo, Alessandro Tozzi & Paolo Calabresi. (2020) From Synaptic Dysfunction to Neuroprotective Strategies in Genetic Parkinson’s Disease: Lessons From LRRK2. Frontiers in Cellular Neuroscience 14.
Crossref
Christian Johannes Gloeckner & Pablo Porras. (2020) Guilt-by-Association – Functional Insights Gained From Studying the LRRK2 Interactome. Frontiers in Neuroscience 14.
Crossref
Mimi Yang, Lichao Wang, Tao Zhang, An Zhu, Yuqing Sun, Jingwei Zhao, Dan Liu, Qi Wang & Kewu Zeng. (2020) Different proteomic profiles of cinnabar upon therapeutic and toxic exposure reveal distinctive biological manifestations. Journal of Ethnopharmacology 253, pages 112668.
Crossref
Giulia Lamonaca & Mattia Volta. (2020) Alpha-Synuclein and LRRK2 in Synaptic Autophagy: Linking Early Dysfunction to Late-Stage Pathology in Parkinson’s Disease. Cells 9:5, pages 1115.
Crossref
Xu Hou, Jens O. Watzlawik, Fabienne C. Fiesel & Wolfdieter Springer. (2020) Autophagy in Parkinson's Disease. Journal of Molecular Biology 432:8, pages 2651-2672.
Crossref
Algerta Marku, Maria Dolores Perez Carrion, Francesca Pischedda, Antonella Marte, Zeila Casiraghi, Paola Marciani, Felix von Zweydorf, Christian Johannes Gloeckner, Franco Onofri, Carla Perego & Giovanni Piccoli. (2020) The LRRK2 N-terminal domain influences vesicle trafficking: impact of the E193K variant. Scientific Reports 10:1.
Crossref
Maria Antonietta Casu, Ignazia Mocci, Raffaella Isola, Augusta Pisanu, Laura Boi, Giovanna Mulas, Nigel H. Greig, Maria Dolores Setzu & Anna R. Carta. (2020) Neuroprotection by the Immunomodulatory Drug Pomalidomide in the Drosophila LRRK2WD40 Genetic Model of Parkinson’s Disease. Frontiers in Aging Neuroscience 12.
Crossref
Noémie Cresto, Marie-Claude Gaillard, Camille Gardier, Francesco Gubinelli, Elsa Diguet, Déborah Bellet, Laurine Legroux, Julien Mitja, Gwenaëlle Auregan, Martine Guillermier, Charlène Josephine, Caroline Jan, Noëlle Dufour, Alain Joliot, Philippe Hantraye, Gilles Bonvento, Nicole Déglon, Alexis-Pierre Bemelmans, Karine Cambon, Géraldine Liot & Emmanuel Brouillet. (2020) The C-terminal domain of LRRK2 with the G2019S mutation is sufficient to produce neurodegeneration of dopaminergic neurons in vivo. Neurobiology of Disease 134, pages 104614.
Crossref
Yan Li & Mark R. Cookson. (2019) Proteomics; applications in familial Parkinson's disease. Journal of Neurochemistry 151:4, pages 446-458.
Crossref
Antonella Marte, Isabella Russo, Claudia Rebosio, Pierluigi Valente, Elisa Belluzzi, Francesca Pischedda, Caterina Montani, Chiara Lavarello, Andrea Petretto, Ernesto Fedele, Pietro Baldelli, Fabio Benfenati, Giovanni Piccoli, Elisa Greggio & Franco Onofri. (2019) Leucine‐rich repeat kinase 2 phosphorylation on synapsin I regulates glutamate release at pre‐synaptic sites. Journal of Neurochemistry 150:3, pages 264-281.
Crossref
Natalie Connor-Robson, Heather Booth, Jeffrey G. Martin, Benbo Gao, Kejie Li, Natalie Doig, Jane Vowles, Cathy Browne, Laura Klinger, Peter Juhasz, Christine Klein, Sally A. Cowley, Paul Bolam, Warren Hirst & Richard Wade-Martins. (2019) An integrated transcriptomics and proteomics analysis reveals functional endocytic dysregulation caused by mutations in LRRK2. Neurobiology of Disease 127, pages 512-526.
Crossref
Dong Hwan Ho, Daleum Nam, Mi Kyoung Seo, Sung Woo Park, Ilhong Son & Wongi Seol. (2019) Leucine-rich Repeat Kinase 2 (LRRK2) Phosphorylates Rab10 in Glia and Neurons. Biomedical Science Letters 25:2, pages 177-184.
Crossref
Wongi Seol, Daleum Nam & Ilhong Son. (2019) Rab GTPases as Physiological Substrates of LRRK2 Kinase. Experimental Neurobiology 28:2, pages 134-145.
Crossref
Ping-Yue Pan, Yingbo Zhu, Yuan Shen & Zhenyu Yue. (2019) Crosstalk between presynaptic trafficking and autophagy in Parkinson's disease. Neurobiology of Disease 122, pages 64-71.
Crossref
Pengfei ZhangYing FanHeng RuLi WangVenkat Giri MagupalliSusan S. Taylor, Dario R. AlessiHao Wu. (2019) Crystal structure of the WD40 domain dimer of LRRK2. Proceedings of the National Academy of Sciences 116:5, pages 1579-1584.
Crossref
Miho Araki, Genta Ito & Taisuke Tomita. (2018) Physiological and pathological functions of LRRK2: implications from substrate proteins. Neuronal Signaling 2:4.
Crossref
Sandra‐Fausia Soukup, Roeland Vanhauwaert & Patrik Verstreken. (2018) Parkinson's disease: convergence on synaptic homeostasis. The EMBO Journal 37:18.
Crossref
Maria Perez Carrion, Francesca Pischedda, Alice Biosa, Isabella Russo, Letizia Straniero, Laura Civiero, Marianna Guida, Christian J. Gloeckner, Nicola Ticozzi, Cinzia Tiloca, Claudio Mariani, Gianni Pezzoli, Stefano Duga, Irene Pichler, Lifeng Pan, John E. Landers, Elisa Greggio, Michael W. Hess, Stefano Goldwurm & Giovanni Piccoli. (2018) The LRRK2 Variant E193K Prevents Mitochondrial Fission Upon MPP+ Treatment by Altering LRRK2 Binding to DRP1. Frontiers in Molecular Neuroscience 11.
Crossref
Joseph McInnes, Keimpe Wierda, An Snellinx, Laura Bounti, Yu-Chun Wang, Ilie-Cosmin Stancu, Nuno Apóstolo, Kris Gevaert, Ilse Dewachter, Tara L. Spires-Jones, Bart De Strooper, Joris De Wit, Lujia Zhou & Patrik Verstreken. (2018) Synaptogyrin-3 Mediates Presynaptic Dysfunction Induced by Tau. Neuron 97:4, pages 823-835.e8.
Crossref
Surbhi Sharma, Richard J. Young, Jingchun Chen, Xiangning Chen, Edwin C. Oh & Martin R. Schiller. (2018) Minimotifs dysfunction is pervasive in neurodegenerative disorders. Alzheimer's & Dementia: Translational Research & Clinical Interventions 4:1, pages 414-432.
Crossref
Darcy Litteljohn, Chris Rudyk, Zach Dwyer, Kyle Farmer, Teresa Fortin & Shawn Hayley. (2018) The impact of murine LRRK2 G2019S transgene overexpression on acute responses to inflammatory challenge. Brain, Behavior, and Immunity 67, pages 246-256.
Crossref
Erin N Bobeck, Ivone Gomes, Darlene Pena, Kirstie A Cummings, Roger L Clem, Mihaly Mezei & Lakshmi A Devi. (2017) The BigLEN-GPR171 Peptide Receptor System Within the Basolateral Amygdala Regulates Anxiety-Like Behavior and Contextual Fear Conditioning. Neuropsychopharmacology 42:13, pages 2527-2536.
Crossref
Ping-Yue Pan, Xianting Li, Jing Wang, James Powell, Qian Wang, Yuanxi Zhang, Zhaoyu Chen, Bridget Wicinski, Patrick Hof, Timothy A. Ryan & Zhenyu Yue. (2017) Parkinson's Disease-Associated LRRK2 Hyperactive Kinase Mutant Disrupts Synaptic Vesicle Trafficking in Ventral Midbrain Neurons. The Journal of Neuroscience 37:47, pages 11366-11376.
Crossref
Bikash Choudhary, Madhushree Kamak, Neena Ratnakaran, Jitendra Kumar, Anjali Awasthi, Chun Li, Ken Nguyen, Kunihiro Matsumoto, Naoki Hisamoto & Sandhya P. Koushika. (2017) UNC-16/JIP3 regulates early events in synaptic vesicle protein trafficking via LRK-1/LRRK2 and AP complexes. PLOS Genetics 13:11, pages e1007100.
Crossref
Kushal Sejwal, Mohamed Chami, Hervé Rémigy, Renée Vancraenenbroeck, William Sibran, Rosmarie Sütterlin, Paul Baumgartner, Robert McLeod, Marie-Christine Chartier-Harlin, Veerle Baekelandt, Henning Stahlberg & Jean-Marc Taymans. (2017) Cryo-EM analysis of homodimeric full-length LRRK2 and LRRK1 protein complexes. Scientific Reports 7:1.
Crossref
Maria Dolores Perez Carrion, Silvia Marsicano, Federica Daniele, Antonella Marte, Francesca Pischedda, Eliana Di Cairano, Ester Piovesana, Felix von Zweydorf, Elisabeth Kremmer, Christian Johannes Gloeckner, Franco Onofri, Carla Perego & Giovanni Piccoli. (2017) The LRRK2 G2385R variant is a partial loss-of-function mutation that affects synaptic vesicle trafficking through altered protein interactions. Scientific Reports 7:1.
Crossref
Weirong R Xing, Helen Goodluck, Canjun Zeng & Subburaman Mohan. (2017) Role and mechanism of action of leucine-rich repeat kinase 1 in bone. Bone Research 5:1.
Crossref
James W. Jr. Maas, Jing Yang & Robert H. Edwards. (2017) Endogenous Leucine-Rich Repeat Kinase 2 Slows Synaptic Vesicle Recycling in Striatal Neurons. Frontiers in Synaptic Neuroscience 9.
Crossref
Un-Beom Kang & Jarrod A. Marto. (2017) Leucine-rich repeat kinase 2 and Parkinson's disease. PROTEOMICS 17:1-2, pages 1600092.
Crossref
Giambattista Guaitoli, Bernd K. Gilsbach, Francesco Raimondi & Christian Johannes Gloeckner. (2016) First model of dimeric LRRK2: the challenge of unrevealing the structure of a multidomain Parkinson's-associated protein. Biochemical Society Transactions 44:6, pages 1635-1641.
Crossref
Jennifer Stanic, Manuela Mellone, Maria Daniela Cirnaru, Maria Perez-Carrion, Elisa Zianni, Monica Di Luca, Fabrizio Gardoni & Giovanni Piccoli. (2016) LRRK2 phosphorylation level correlates with abnormal motor behaviour in an experimental model of levodopa-induced dyskinesias. Molecular Brain 9:1.
Crossref
Elisa Belluzzi, Adriano Gonnelli, Maria-Daniela Cirnaru, Antonella Marte, Nicoletta Plotegher, Isabella Russo, Laura Civiero, Susanna Cogo, Maria Perèz Carrion, Cinzia Franchin, Giorgio Arrigoni, Mariano Beltramini, Luigi Bubacco, Franco Onofri, Giovanni Piccoli & Elisa Greggio. (2016) LRRK2 phosphorylates pre-synaptic N-ethylmaleimide sensitive fusion (NSF) protein enhancing its ATPase activity and SNARE complex disassembling rate. Molecular Neurodegeneration 11:1.
Crossref
Canjun ZengHelen GoodluckXuezhong QinBo Liu, Subburaman MohanWeirong Xing. (2016) Leucine-rich repeat kinase-1 regulates osteoclast function by modulating RAC1/Cdc42 Small GTPase phosphorylation and activation. American Journal of Physiology-Endocrinology and Metabolism 311:4, pages E772-E780.
Crossref
Florian Glenewinkel, Michael J. Cohen, Cason R. King, Sophie Kaspar, Simone Bamberg-Lemper, Joe S. Mymryk & Walter Becker. (2016) The adaptor protein DCAF7 mediates the interaction of the adenovirus E1A oncoprotein with the protein kinases DYRK1A and HIPK2. Scientific Reports 6:1.
Crossref
Tommaso Schirinzi, Graziella Madeo, Giuseppina Martella, Marta Maltese, Barbara Picconi, Paolo Calabresi & Antonio Pisani. (2016) Early synaptic dysfunction in Parkinson's disease: Insights from animal models. Movement Disorders 31:6, pages 802-813.
Crossref
Cade Bedford, Catherine Sears, Maria Perez-Carrion, Giovanni Piccoli & Steven B. Condliffe. (2016) LRRK2 Regulates Voltage-Gated Calcium Channel Function. Frontiers in Molecular Neuroscience 9.
Crossref
Arianna Bellucci, Nicola Biagio Mercuri, Annalena Venneri, Gaia Faustini, Francesca Longhena, Marina Pizzi, Cristina Missale & PierFranco Spano. (2016) Review: Parkinson's disease: from synaptic loss to connectome dysfunction. Neuropathology and Applied Neurobiology 42:1, pages 77-94.
Crossref
Rebekah G. LangstonIakov N. RudenkoMark R. Cookson. (2016) The function of orthologues of the human Parkinson's disease gene LRRK2 across species: implications for disease modelling in preclinical research . Biochemical Journal 473:3, pages 221-232.
Crossref
Dong Hwan Ho, Jihoon Jang, Eun-hye Joe, Ilhong Son, Hyemyung Seo & Wongi Seol. (2016) G2385R and I2020T Mutations Increase LRRK2 GTPase Activity. BioMed Research International 2016, pages 1-8.
Crossref
A. Mamais & M.R. Cookson. 2016. Handbook of Basal Ganglia Structure and Function, Second Edition. Handbook of Basal Ganglia Structure and Function, Second Edition 839 855 .
Pablo Porras, Margaret Duesbury, Antonio Fabregat, Marius Ueffing, Sandra Orchard, Christian Johannes Gloeckner & Henning Hermjakob. (2015) A visual review of the interactome of LRRK2: Using deep‐curated molecular interaction data to represent biology. PROTEOMICS 15:8, pages 1390-1404.
Crossref
Jorge S. Valadas, Melissa Vos & Patrik Verstreken. (2015) Therapeutic strategies in Parkinson's disease: what we have learned from animal models. Annals of the New York Academy of Sciences 1338:1, pages 16-37.
Crossref
Mian Cao, Ira Milosevic, Silvia Giovedi & Pietro De Camilli. (2014) Upregulation of Parkin in Endophilin Mutant Mice. The Journal of Neuroscience 34:49, pages 16544-16549.
Crossref
P. Gómez-Suaga, E. Fdez, B. Fernández, M. Martínez-Salvador, M. Blanca Ramírez, J. Madero-Pérez, P. Rivero-Ríos, J.M. Fuentes & S. Hilfiker. (2014) Novel insights into the neurobiology underlying LRRK2-linked Parkinson's disease. Neuropharmacology 85, pages 45-56.
Crossref
Dayne A. Beccano-Kelly, Naila Kuhlmann, Igor Tatarnikov, Mattia Volta, Lise N. Munsie, Patrick Chou, Li-Ping Cao, Heather Han, Lucia Tapia, Matthew J. Farrer & Austen J. Milnerwood. (2014) Synaptic function is modulated by LRRK2 and glutamate release is increased in cortical neurons of G2019S LRRK2 knock-in mice. Frontiers in Cellular Neuroscience 8.
Crossref
Maria D. Cirnaru, Antonella Marte, Elisa Belluzzi, Isabella Russo, Martina Gabrielli, Francesco Longo, Ludovico Arcuri, Luca Murru, Luigi Bubacco, Michela Matteoli, Ernesto Fedele, Carlo Sala, Maria Passafaro, Michele Morari, Elisa Greggio, Franco Onofri & Giovanni Piccoli. (2014) LRRK2 kinase activity regulates synaptic vesicle trafficking and neurotransmitter release through modulation of LRRK2 macro-molecular complex. Frontiers in Molecular Neuroscience 7.
Crossref
Amaia M. Arranz, Lore Delbroek, Kristof Van Kolen, Marco R. Guimarães, Wim Mandemakers, Guy Daneels, Samer Matta, Sara Calafate, Hamdy Shaban, Pieter Baatsen, Pieter-Jan De Bock, Kris Gevaert, Pieter Vanden Berghe, Patrik Verstreken, Bart De Strooper & Diederik Moechars. (2014) LRRK2 functions in synaptic vesicle endocytosis through a kinase-dependent mechanism. Journal of Cell Science.
Crossref
Paul Galatsis, Jaclyn L. Henderson, Bethany L. Kormos & Warren D. Hirst. 2016. Novel Therapeutic Approaches to the Treatment of Parkinson’s Disease. Novel Therapeutic Approaches to the Treatment of Parkinson’s Disease 111 148 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.